segunda-feira, 9 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

GE Aerospace and Grupo Aeroportuario Del Pacifico have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
GE Aerospace and Grupo Aeroportuario Del Pacifico have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – February 2, 2026 – Zacks Equity Research shares GE Aerospace GE as the Bull of the Day and Grupo Aeroportuario Del Pacífico PAC as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Grupo Aeroportuario Del Pacifico has missed bottom-line expectations for seven consecutive quarters with an average EPS surprise of -6% in its last four quarterly reports.

    80% confidence
  • GE's balance sheet carries over $12 billion in cash and $130 billion in total assets versus $111 billion in total liabilities.

    80% confidence
  • Meta's GEM model improvements drove a 3.5% lift in ad clicks on Facebook and more than 1% gain in conversions on Instagram in Q4 2025.

    80% confidence
  • GE Aerospace has soared over +280% in the last year and investors may be more inclined to pay a premium after a pullback from an all-time high of $332 a share in early January.

    80% confidence
  • Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000 versus the S&P's +7.7% average annual gain.

    80% confidence
  • FY27 EPS projections of $8.55 would reflect 200% growth in five years compared to $2.81 per share in 2021.

    80% confidence
  • The consensus for GE's FY26 EPS has risen above its guidance range to $7.45 compared to $7.15 a week ago.

    80% confidence
  • GE has exceeded the Zacks EPS Consensus for 13 consecutive quarters, posting an average earnings surprise of 14.27% in its last four quarterly reports.

    80% confidence
  • Meta shares climbed 6.6% in the trailing 12 months, underperforming the broader Zacks Computer and Technology sector's return of 27.8%.

    80% confidence
  • Meta's advertising revenues in 2025 increased 22.1% from 2024 to $196.18 billion, accounting for 97.6% of total revenues.

    80% confidence
  • GE's total backlog reached roughly $190 billion, up nearly $20 billion year-over-year, with Q4 orders up 74% to $27 billion.

    80% confidence
  • PAC holds a Zacks Rank #5 (Strong Sell) rating.

    80% confidence
  • Meta plans to complete the rollout of ads in WhatsApp Status throughout 2026.

    80% confidence
  • GE Aerospace's FY26 and FY27 EPS estimates have risen over 6% in the last two months.

    80% confidence
  • Meta Platforms holds a Zacks Rank #3 (Hold) rating.

    80% confidence
  • GAP's EPS is expected to be up 7% for FY25 and projected to increase another 27% in FY26 to $13.14 per share, but revisions are lower over the last 60 days.

    80% confidence
  • Meta, Alphabet, and Amazon are expected to absorb a majority of global ad spending by 2030.

    80% confidence
  • GAP's FY26 sales are projected to slow to a growth rate of 4%.

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,558 documentos-fonte arquivados
Consulte estes dados → isubstrate.com